BEI Medical Systems Announces 24-Month Follow-up Results for Its HTA Menorrhagia Treatment System; Achieves 95.5% Patient Satisfaction Rate.

Business Editors

TETERBORO, N.J.--(BUSINESS WIRE)--Nov. 29, 2001

BEI Medical Systems Company, Inc. (NASDAQ: BMED) announced its 24-month follow-up results from the Hydro ThermAblator(R)(HTA) phase III multi-center clinical trial at the 30th annual AAGL Global Congress of Gynecologic Endoscopy in San Francisco.

The FDA-approved HTA enables physicians to perform endometrial ablation, the removal or destruction of the lining of the uterus, as a minimally invasive treatment alternative to the approximately 150,000 hysterectomies performed annually in the United States for menorrhagia (excessive uterine bleeding) from benign causes. The HTA treatment can be performed on an outpatient basis in a hospital, at an ambulatory surgery center or in a physician's office. Annually, close to 2.5 million women in the U.S. seek medical treatment for excessive menstrual bleeding.

Most notable of BEI's comprehensive educational program at the AAGL Congress, which consisted of 22 presentations delivered by ten prominent physicians, was the HTA's 24-month follow-up results. Dr. Stephen L. Corson of Jefferson Medical College, Philadelphia, and medical director of BEI Medical Systems, reported that of the women for which 24 month data was available, 47.6% indicated a complete cessation of menstrual bleeding and an additional 44.2% had a reduction in bleeding to acceptable levels. Overall, 95.5% of the women continued to be satisfied with their results two years after treatment and 92.5% reported alleviation of menstrual discomfort.

Richard Turner, president and CEO of BEI Medical Systems, stated, "The AAGL Global Congress was an important opportunity for BEI to demonstrate the features, benefits and outstanding results of the HTA to many of the world's most distinguished gynecologists. The 24-month data demonstrates long-term satisfaction with the results of the HTA treatment. We are optimistic for the prospects for continued adoption of HTA therapy as the treatment of choice for excessive menstrual bleeding."

The AAGL Global Congress was sponsored by the American Association of Gynecological Laparoscopists on November 15-19, 2001 in San Francisco, California. The event is held each year to assist physicians in providing the safest, most therapeutic, and most economical surgical care available for women by helping doctors increase the depth and breadth of their surgical skills.

About BEI Medical Systems

BEI Medical Systems Company, Inc., is a company focused on gynecology. The company has received approval from the FDA to market in the United States its sole product, the Hydro ThermAblator (HTA), a proprietary system that is intended to treat menorrhagia, or dysfunctional uterine bleeding. BEI Medical Systems(R), Hydro ThermAblator(R) and HTA(R) are registered trademarks of BEI Medical Systems Company, Inc., in the United States and certain foreign countries. For more information, please visit the company's web site at www.beimedical.com.

Except for historical information, this news release may be deemed to contain forward-looking statements that involve risks and uncertainties, including statements with respect to: acceptance and pricing of the HTA system; the impact of competitive products and pricing; the company's ability to raise additional capital on terms favorable to the company, or at all; and general economic conditions as they affect BEI Medical's customers, as well as other risks detailed from time to time in the company's reports to the Securities and Exchange Commission, including the company's Form 10-K annual report.